(290 days)
Not Found
Unknown
The summary describes image processing and quantitative analysis but does not explicitly mention AI or ML. While segmentation and quantification could potentially utilize AI/ML, the document does not provide enough detail to confirm this.
No.
The device is described as software for advanced visualization and quantitative analysis, supporting diagnostics by enabling segmentation, quantification, review, and reporting of cardiac structures based on echocardiographic images. It does not actively treat or alleviate a disease, but rather provides tools for diagnosis and analysis.
Yes
Explanation: The "Intended Use / Indications for Use" section explicitly states that the software is "to support physicians with diagnostics" and the "Device Description" section describes it as a "web-based solution for diagnostic echocardiography."
Yes
The device description explicitly states "Caas Qardia is an image post-processing software package" and "Caas Qardia is a web-based solution". There is no mention of accompanying hardware components being part of the device itself.
Based on the provided information, this device is not an In Vitro Diagnostic (IVD).
Here's why:
- IVDs are used to examine specimens from the human body. The intended use and device description clearly state that Caas Qardia processes and analyzes echocardiographic images of cardiac structures. It does not analyze biological samples like blood, urine, or tissue.
- The purpose is image analysis and visualization. The software is designed for advanced visualization, quantitative analysis, segmentation, and reporting based on medical images. This falls under the category of medical image processing and analysis software, not IVD.
Therefore, while it is a medical device used for diagnostic purposes, it does not meet the definition of an In Vitro Diagnostic.
N/A
Intended Use / Indications for Use
Standalone software for medical image analysis intended visualization and quantitative analysis in adult populations to support physicians with diagnostics by means of enabling segmentation, review, and reporting of cardiac structures based on multi-dimensional images. Caas Qardia facilitates the following use:
. Segmentation of cardiovascular structures
Quantification and reporting of cardiovascular function and structure
When the results provided by Caas Qardia are used in a clinical setting to support clinical decision-making, the results are explicitly not to be regarded as the sole, irrefutable basis for clinical decision- making.
Product codes (comma separated list FDA assigned to the subject device)
LLZ
Device Description
Caas Qardia is an image post-processing software package for diagraphy, which offers functionality to view echocardiographic images, to segment cardiovascular structures in these images, to analyze and quantify these cardiovascular structures and to present the analysis results in different formats.
Caas Qardia is a web-based solution for diagnostic echocardiography, intended for usage in a network environment or standalone usage. Caas Qardia is composed of the following key analysis features:
- -Study selection (from PACS server or local data)
- -Image viewing
- -Left ventricular ejection fraction analysis
- -Left ventricular strain analysis
- -Cardiac geometric measurements and velocity measurements
- -Reporting
- -Export of results
Results can be displayed on the screen, printed, or saved in a variety of formats to hard disk, network, PACS system or CD. Results and clinical images with overlay can also be printed as a hardcopy and exported in various electronic formats.
Mentions image processing
Caas Qardia is an image post-processing software package for diagraphy, which offers functionality to view echocardiographic images, to segment cardiovascular structures in these images, to analyze and quantify these cardiovascular structures and to present the analysis results in different formats.
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
echocardiographic images
Anatomical Site
cardiovascular structures
Indicated Patient Age Range
adult populations
Intended User / Care Setting
medical specialist to support clinical decision making of cardiovascular conditions.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Performance testing to demonstrate substantial equivalence to the predicate device was conducted. ED and ES volume calculation and EF determination, directly resulting from segmented contours on clinical images are compared to ED and ES volumes and EF resulting from manually annotated ED and ES contours.
The global longitudinal strain was evaluated on clinical datasets by performing a comparative test of the results against the predicate device.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Performance testing to demonstrate substantial equivalence to the predicate device was conducted. ED and ES volume calculation and EF determination, directly resulting from segmented contours on clinical images are compared to ED and ES volumes and EF resulting from manually annotated ED and ES contours. The acceptance criteria for ED and ES volume, and EF calculations were as follows: A Pearson correlation of 0.7 or higher, an ICC of at least 0.6 and a bias not more than one pooled standard deviation from zero from the comparison with literature. For all values these acceptance criteria were met.
The global longitudinal strain was evaluated on clinical datasets by performing a comparative test of the results against the predicate device. The acceptance criteria for global longitudinal strain were as follows: A Pearson correlation of 0.7 or higher and an ICC of at least 0.6. For all values these acceptance criteria were met.
Inter- and intra-observer variability was evaluated for the ED and ES volume calculation, EF determination and global longitudinal strain (GLS) calculation. Both inter-observer variability demonstrated acceptable performance with a Pearson correlation higher than 0.9.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
A Pearson correlation of 0.7 or higher, an ICC of at least 0.6 and a bias not more than one pooled standard deviation from zero from the comparison with literature.
A Pearson correlation of 0.7 or higher and an ICC of at least 0.6.
Pearson correlation higher than 0.9.
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 892.2050 Medical image management and processing system.
(a)
Identification. A medical image management and processing system is a device that provides one or more capabilities relating to the review and digital processing of medical images for the purposes of interpretation by a trained practitioner of disease detection, diagnosis, or patient management. The software components may provide advanced or complex image processing functions for image manipulation, enhancement, or quantification that are intended for use in the interpretation and analysis of medical images. Advanced image manipulation functions may include image segmentation, multimodality image registration, or 3D visualization. Complex quantitative functions may include semi-automated measurements or time-series measurements.(b)
Classification. Class II (special controls; voluntary standards—Digital Imaging and Communications in Medicine (DICOM) Std., Joint Photographic Experts Group (JPEG) Std., Society of Motion Picture and Television Engineers (SMPTE) Test Pattern).
0
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food & Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
Pie Medical Imaging B.V. % Annemiek Bouts Regulatory Affairs Coordinator Philipsweg 1 Maastricht, Limburg 6227 AJ NETHERLANDS
Re: K212376
May 16, 2022
Trade/Device Name: Caas Qardia Regulation Number: 21 CFR 892.2050 Regulation Name: Medical image management and processing system Regulatory Class: Class II Product Code: LLZ Dated: April 14, 2022 Received: April 18, 2022
Dear Annemiek Bouts:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for
1
devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely.
Jessica Lamb, Ph.D. Assistant Director Imaging Software Team DHT8B: Division of Radiological Imaging Devices and Electronic Products OHT8: Office of Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K212376
Device Name Caas Qardia
Indications for Use (Describe)
Standalone software for medical intended for advanced visualization and quantitative analysis in adult populations to support physicians with diagnostics by means of enabling segmentation, quantification, review, and reporting of cardiac structures based on multi-dimensional echocardiographic images. Caas Qardia facilitates the following use:
· Segmentation of cardiovascular structures
· Calculation of quantitative indices describing cardiovascular function and structure
When the results provided by Caas Qardia are used in a clinical decision making, the results are explicitly not to be regarded as the sole, irrefutable basis for clinical decision making.
Type of Use (Select one or both, as applicable)
X Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) Summary
Caas Qardia – K212376
Pie Medical Imaging BV
| I - General Information | ||
|---|---|---|
| Submitter/Owner Name | Pie Medical Imaging BV | |
| Address | Philipsweg 1, 6227 AJ Maastricht, The Netherlands | |
| Phone Number | +31 43 32 81 328 | |
| Contact Person | Annemiek Bouts, Regulatory Affairs Coordinator | |
| Email Address | reg@pie.nl | |
| Preparation Date | 14-Apr-22 | |
| Trade Name | Caas Qardia | |
| Common Name | Caas Qardia | |
| Classification | Regulation Name: | Image Processing System |
| Regulation Class: | Class II | |
| Regulation Number: | 21 CFR 892.2050 | |
| Classification Product Code: | LLZ | |
| Predicate Device | TomTec Arena (K201632, Image Processing System, 21 CFR 892.2050, LLZ) |
II - Device Description
Caas Qardia is an image post-processing software package for diagraphy, which offers functionality to view echocardiographic images, to segment cardiovascular structures in these images, to analyze and quantify these cardiovascular structures and to present the analysis results in different formats.
Caas Qardia is a web-based solution for diagnostic echocardiography, intended for usage in a network environment or standalone usage. Caas Qardia is composed of the following key analysis features:
- -Study selection (from PACS server or local data)
- -Image viewing
- -Left ventricular ejection fraction analysis
- -Left ventricular strain analysis
- -Cardiac geometric measurements and velocity measurements
- -Reporting
- -Export of results
Results can be displayed on the screen, printed, or saved in a variety of formats to hard disk, network, PACS system or CD. Results and clinical images with overlay can also be printed as a hardcopy and exported in various electronic formats.
III - Intended Use and Indications for Use
Intended Use
Standalone diagnostic bioimaging software is intended to measure and visualize cardiovascular structures.
Indications for Use
Standalone software for medical image analysis intended visualization and quantitative analysis in adult populations to support physicians with diagnostics by means of enabling segmentation, review, and reporting of cardiac structures based on multi-dimensional images. Caas Qardia facilitates the following use:
- . Segmentation of cardiovascular structures
- Quantification and reporting of cardiovascular function and structure
When the results provided by Caas Qardia are used in a clinical setting to support clinical decision-making, the results are explicitly not to be regarded as the sole, irrefutable basis for clinical decision- making.
4
IV - Substantial equivalence comparison
The Tomtec Arena clinical software package (K201632) was selected as a predicate device specifically for its ability for review, quantification and reporting of cardiovascular structures and function based on echocardiographic images. Unlike Tomtec Arena, which can be used for cardiovascular, fetal and abdominal on medical data acquired with different modalities, Caas Qardia can only be used for the analysis of cardiovascular structures in adult populations acquired with echocardiographic images. The Tomtec Arena device, amongst others, consists of analysis workflows for left ventricular ejection fraction analysis, left ventricular strain analysis, cardiac performance analysis (geometric and velocity measurements) and features like image viewing and reporting similar to the Caas Qardia device.
The selected device has technological features and characteristics comparable to Caas Qardia and is intended to be used or under supervision of a medical specialist to support clinical decision making of cardiovascular conditions.
The basic features and technology of the new Caas Qardia product are the same in terms of intended use and indications for use and have the same technological characteristics as the predicate device Tomtec Arena (K201632).
Both Caas Qardia and Tomtec Arena (K201632) software applications use the same types of data (echocardiographic images) and operating principles for the user and technology regarding data import, contour definition, image display and storage of results.
V - Performance Data
Caas Qardia was developed and tested according to PMI's design and has been extensively tested for safety and performance. Non-clinical verification of the Caas Qardia showed that the system requirements – derived from indications for use – as well as risk control measures were implemented correctly, and that the device meets its specifications including conformance to the following recognized consensus standards:
| Consensus standard | Recognition
number |
|----------------------------------------------------------------------------------------------|-----------------------|
| ISO 14971:2019 – Medical Devices – Application of Risk Management to Medical Devices | 5-125 |
| IEC 62304:2015 – Medical Device Software – Software Life Cycle Processes | 13-79 |
| IEC 62366-1:2015 – Medical Devices – Application of Usability Engineering to Medical Devices | 5-114 |
| NEMA PS 3.1-3.20 (2016) - Digital Imaging and Communication in Medicine (DICOM) | 12-300 |
| IEC 82304-1:2016 – Health Software – Part 1: General Requirements for Product Safety | 13-97 |
In addition, Caas Qardia is compliant with the international standard ISO13485:2016.
Usability testing is performed in accordance with IEC62366 which demonstrated that the use Cars Qardia for the purpose it was developed for.
Performance testing to demonstrate substantial equivalence to the predicate device was conducted. ED and ES volume calculation and EF determination, directly resulting from segmented contours on clinical images are compared to ED and ES volumes and EF resulting from manually annotated ED and ES contours. The acceptance criteria for ED and ES volume, and EF calculations were as follows: A Pearson correlation of 0.7 or higher, an ICC of at least 0.6 and a bias not more than one pooled standard deviation from zero from the comparison with literature. For all values these acceptance criteria were met.
The global longitudinal strain was evaluated on clinical datasets by performing a comparative test of the results against the predicate device. The acceptance criteria for global longitudinal strain were as follows: A Pearson correlation of 0.7 or higher and an ICC of at least 0.6. For all values these acceptance criteria were met.
Inter- and intra-observer variability was evaluated for the ED and ES volume calculation, EF determination and global longitudinal strain (GLS) calculation. Both inter-observer variability demonstrated acceptable performance with a Pearson correlation higher than 0.9.
5
Image /page/5/Picture/0 description: The image shows the logo for PIE Medical Imaging. The logo is set against a blue background. The text "PIE MEDICAL IMAGING" is stacked vertically, with each word on a separate line. The word "IMAGING" is slightly larger than the other words.
The verification and validation results demonstrate the safety and effectiveness of Caas Qardia in relation to its intended use and indications for use and therefore Caas Qardia can be considered as safe and effective as its predicate devices.
VI - Conclusion
Based on the application of risk management and performance testing inherent to PMI's QA system (compliant with recognized standards as stated above) the conclusion is that Caas Qardia is as safe and effective as its predicate devices in terms of indications for use, technological characteristics, measurements, and operating environment and does not raise any new issues related to safety and effectiveness compared to the predicate devices.